Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
04:14:15 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Q:BIIB - BIOGEN INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BIIB - Q3.0190.00·200.206.2201.18+15.828.53,404.8668,05342,627187.01  202.41  184.60190.20  110.03519:50:53Feb 0415 min RT 2¢

Recent Trades - Last 10 of 42627
Time ETExPriceChangeVolume
19:50:53Q198.602113.242110
19:38:52Q200.1014.745
19:34:40Q196.0110.655
19:34:40Q196.0110.653
19:34:40Q196.0110.652
19:34:40Q196.0110.651
19:23:47Q196.0110.6510
19:16:49Q196.0110.651
19:12:57Q197.2811.926
19:12:42Q195.715310.355319

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-02-04 07:30U:BIIBNews ReleaseNature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
2026-01-28 07:30U:BIIBNews ReleaseBiogen's Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
2026-01-25 18:30U:BIIBNews ReleaseFDA Accepts LEQEMBI(TM) IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
2026-01-12 11:05U:BIIBNews ReleaseBiogen Receives European Commission Approval for High Dose Regimen of SPINRAZA(TM) (nusinersen) for Spinal Muscular Atrophy
2025-12-22 11:20U:BIIBNews ReleaseThe Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
2025-12-05 09:00U:BIIBNews ReleaseStoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
2025-12-05 09:00U:BIIBNews ReleaseBiogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
2025-12-03 18:10U:BIIBNews ReleaseEisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(TM) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025
2025-12-02 16:40U:BIIBNews ReleaseNew Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI(TM) (lecanemab-irmb) on Neurotoxic Abeta Protofibrils in CSF
2025-12-01 07:30U:BIIBNews ReleaseStoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
2025-11-25 07:30U:BIIBNews ReleaseEisai Completes Rolling Submission to U.S. FDA for LEQEMBI(TM) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
2025-11-24 07:30U:BIIBNews ReleaseBiogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions
2025-11-20 07:30U:BIIBNews ReleaseBiogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer's Disease Conference
2025-11-17 07:30U:BIIBNews ReleaseBiogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
2025-11-17 06:00U:BIIBNews ReleaseHigh Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
2025-11-14 16:05U:BIIBNews ReleaseBiogen Completes Acquisition of Alcyone Therapeutics
2025-11-03 07:30U:BIIBNews ReleaseBiogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025
2025-10-24 07:31U:BIIBNews ReleaseBiogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio
2025-10-22 07:30U:BIIBNews ReleaseBiogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
2025-10-13 19:30U:BIIBNews ReleaseLEQEMBI(TM) IQLIK(TM)(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"